← All countries · Americas
95%
MCV1
2025 · WHO/UNICEF estimate
87%
DTP3
2025 · WHO/UNICEF estimate
88%
IPV complete
2025 · WHO/UNICEF estimate
86%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
2
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 99%2025 · WHO/UNICEF estimate | 112.8% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 97%2025 · WHO/UNICEF estimate | 106.2% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 87%2025 · WHO/UNICEF estimate | 92.8% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 106.6% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 88%2025 · WHO/UNICEF estimate | 92.0% | D · poor | |
| MCV1First dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 94.1% | B · good | |
| MCV2Second dose of measles-containing vaccine | 78%2025 · WHO/UNICEF estimate | 85.6% | B · good | |
| RCV1First dose of rubella-containing vaccine | 95%2025 · WHO/UNICEF estimate | 94.1% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 86%2025 · WHO/UNICEF estimate | 92.8% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 76%2025 · WHO/UNICEF estimate | 88.2% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 86%2025 · WHO/UNICEF estimate | 92.8% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 106.2%2025 · Administrative (country-reported) | 106.2% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 87%2025 · WHO/UNICEF estimate | 90.7% | A · strong | |
| RotaCRotavirus vaccine, complete series | 83%2025 · WHO/UNICEF estimate | 91.6% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | 83.3%2025 · Administrative (country-reported) | 83.3% | D · poor | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 99%2024 · WHO/UNICEF estimate | 91.1% | D · poor | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 56%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 56%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 24%2025 · WHO/UNICEF estimate | — | too few points | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 6142025 | 53.3per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 22025 | 0.2per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 162025 | 1.4per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | B · good | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02007 | 0per 1,000,000 total population | too few points | no data |
| Invasive meningococcal disease all countries · vaccine evidence | 02023 | 0per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (57 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | General/routine | Esta vacuna fue introducida al esquema nacional en mayo del 2025 como estaba establecido; Todos los niños y niñas que inicien su esquema de Vacunación a partir del 1 de mayo del 2025 | |
| DTWPDTwP (Whole cell) vaccine | 1 | M2 | Risk group(s) | Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años. |
| DTWPDTwP (Whole cell) vaccine | 2 | M4 | Risk group(s) | Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años. |
| DTWPDTwP (Whole cell) vaccine | 3 | M6 | Risk group(s) | Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años. |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | Trabajadores de la salud, enfermos crónicos e inmunosuprimidos |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | Trabajadores de la salud, enfermos crónicos e inmunosuprimidos |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | Trabajadores de la salud, enfermos crónicos e inmunosuprimidos |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | Trabajadores de la salud, enfermos crónicos e inmunosuprimidos |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | Trabajadores de la salud, enfermos crónicos e inmunosuprimidos |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | Trabajadores de la salud, enfermos crónicos e inmunosuprimidos |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y14 | HPV for females only | Sólo vacunación en niñas de 9 a 14 años. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-M11 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | 1st contact | Health workers | Grupos especiales en riesgos: militares, personal de salud, personas que recolectan basura, entre otros; Dosis Única |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | 1st contact | Risk group(s) | Grupos especiales en riesgos: militares, personal de salud, personas que recolectan basura, entre otros; Dosis Única |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | |
| MRMR (Measles and rubella) vaccine | 1 | >=Y2 | Risk group(s) | 2 años y más. Bloqueos alrededor de casos de EFE |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | |
| OPVOPV (Oral polio vaccine) | 5 | Y4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M12 | General/routine | |
| RABIESRabies vaccine | 1 | 1st contact | Risk group(s) | Post-Exp. Mordedura por Animal Rabioso /desc |
| RABIESRabies vaccine | 2 | +D3 | Risk group(s) | Post-Exp. Mordedura por Animal Rabioso /desc |
| RABIESRabies vaccine | 3 | +D7 | Risk group(s) | Post-Exp. Mordedura por Animal Rabioso /desc |
| RABIESRabies vaccine | 4 | +D14 | Risk group(s) | Post-Exp. Mordedura por Animal Rabioso /desc |
| RABIESRabies vaccine | 5 | +D28 | Risk group(s) | Post-Exp. Mordedura por Animal Rabioso /desc |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | 1st contact | Pregnant women | Embarazadas de 27 semanas a 36 semanas. 1 dosis (en cada embarazo). |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >=Y7 | Risk group(s) | Y dosis de refuerzo cada 10 años. Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Risk group(s) | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Risk group(s) | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Pregnant women | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Risk group(s) | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Pregnant women | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Risk group(s) | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | +Y10 | Adults | Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años. |
| YFYF (Yellow fever) vaccine | 1 | Y1-Y59 | Travellers | Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más. |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.